OncoMatch/Clinical Trials/NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Is NCT04603872 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including CD19/BCMA Targeted CAR T-cells and dasatinib and CD19/BCMA Targeted CAR T-cells for multiple myeloma in relapse.
Treatment: CD19/BCMA Targeted CAR T-cells and dasatinib · CD19/BCMA Targeted CAR T-cells — A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
CD19+ ALL
Required: CD19 positive
CD19+ NHL
Required: BCMA (TNFRSF17) positive
BCMA+ MM
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: car-t cell therapy
Lab requirements
Kidney function
creatinine ≤ 176.8 umol/l
Liver function
total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit of normal
Cardiac function
echocardiogram shows left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify